Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

Healthy Clinical Trial

— PK/PD  

Official title:

Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Hypercoagulable States.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01722669
• Other study ID #: 2012P000022
• Status: Completed
• Phase: Early Phase 1
• Start date: May 2012
• Est. completion date: December 2019

Study information

• Verified date: October 2020
• Source: Beth Israel Deaconess Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies

Description:

To compare the absorption and activity of quercetin or isoquercetin with or without ascorbic acid in healthy adults. Oral chews containing quercetin (500mg) or isoquercetin(500 mg total) with or without ascorbic acid will be given. Pharmacokinetic parameters (AUC, Cmax, Tmax, elimination half-life) will be determined over 24 hours (8 time points). Pharmacodynamic inhibition of protein disulfide isomerase activity will also be assessed.

In addition to healthy subjects, a cohort of 10 individuals with antiphospholipid antibodies will participate. These participants will receive isoquercetin 1000 mg and have pharmacodynamics studies performed at time 0 and 4 hours.

All study drugs will be provided by Quercegen Pharma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria

• Subject is willing to participate and provide informed consent

• Subject is considered reliable and capable of adhering to the protocol per the judgment of the Investigator

• Subjects in group D must exhibit good organ reserves (within prior 4 weeks) defined as:

1. Estimated GFR >35 (formula),

2. Platelet count >65 K/uL,

3. Hemoglobin >10.5 grams/dL

4. Total bilirubin <2.0 mg/dL

• Minimum age 18 years old

• Body mass index (BMI) between 18 and 35 kg/m2

• For cohort D (antiphospholipid antibodies) a. Subjects in group D must have at least one positive antiphospholipid antibody within the last 8 weeks and/or previous confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. Positive lupus anticoagulant ii. anticardiolipin antibody IgM or IgG (>40U GPL) iii. anti-ß2 Glycoprotein1 antibody titer (>35 units)

Exclusion Criteria

• Pregnant. If female of child-bearing age, negative urinary pregnancy test prior to dosing of quercetin or isoquercetin

• No history of malabsorptive gastrointestinal disorder

• Currently taking aspirin, NSAIDS, warfarin, low-molecular weight heparin or other anticoagulants (such as direct thrombin inhibitors or factor X inhibitors)

a. Note: Study subjects taking aspirin or NSAIDS, if treating physician concurs, are permitted to enroll if plan to hold for aspirin 10 days or NSAIDS 24 hours prior to dosing of quercetin/isoquercetin

• Prescribed niacin for hyperlipidemia

• Known HIV

• History of sensitivity or intolerance to flavonoids, niacin or ascorbic acid

• May not have uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia

Related Conditions & MeSH terms

• Healthy
• Thrombophilia

Intervention

Drug:
• isoquercetin or quercetin
Single dose PK/PD study

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC	AUC 0-24 hours of measured plasma quercetin aglycone for Arms A1, B1, A2, B2, C Collected at timepoints: baseline and 1, 2, 4, 6, 8, and 24 hours after dose. PK and PDI samples were not measured for Arm D (anti-phospholipid antibody cohort)	24 hours
Secondary	Reductase Activity of PDI Using Dieosin Glutathione Disulfide	Measurement of protein disulfide inhibition in plasma using a fluorescent PDI substrate (dieosin glutathione disulfide)	2 hours. Not measured in D
Secondary	Platelet-induced Thrombin Generation (U/mL)	Thrombin induced thrombin generation measured in patient plasma	4 hours